Modulatory effect of aquaporin 5 on estrogen-induced epithelial-mesenchymal transition in prostate epithelial cells.
This study aimed to examine the effects of AQP5 on estrogen-induced EMT in the prostate. METHODS: Normal prostate (NP) tissue samples without any histopathological changes and BPH tissue samples with pathologically confirmed hyperplasia were obtained. An EMT cell model was subsequently established by adding estradiol (E2) to RWPE-1 cells, after which AQP5 knockdown was performed. Tissue morphological and immunohistochemical features were examined using hematoxylin-eosin and immunohistochemical staining. Western blot analysis was performed to determine the expression of AQPs, estrogen receptors, and EMT-related proteins. Cell proliferation was assessed and supernatants were collected for enzyme-linked immunosorbent assay to determine transforming growth factor-β1 (TGF-β1) concentrations. Immunofluorescence staining was performed to assess protein expressions in RWPE-1 cells. RESULTS: BPH tissues exhibited greater EMT (TGF-β1: 1.362 ± 0.196 vs. 0.107 ± 0.067, P = 0.003; vimentin: 1.581 ± 0.508 vs. 0.221 ± 0.047, P
To analyze the safety of mirabegron add-on therapy in men with overactive bladder symptoms concurrently receiving tamsulosin for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
AbstractPurposeTo present our experience of the patterns of revascularisation of the prostate and efficacy of repeat prostate artery embolisation (rPAE) in patients with recurrence of lower urinary tract symptoms.Materials and MethodsWe retrospectively analysed 12 patients who underwent rPAE at a single centre between November 2015 and March 2020. The patients had their intraprocedural angiography and cone beam CT images as well as their pre-procedural CT retrospectively reviewed to establish the patterns of revascularisation. Clinical follow-up occurred at a minimum of 3 months.Results11/12 patients (91.6%) had sign...
As Prostate Artery Embolization (PAE) for treatment of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH) becomes more commonly performed, operator knowledge of the adverse events is essential to inform patient selection, patient preparation, and post-procedural management. The aim of this article is to the discuss the incidence, presentation, and management of the PAE adverse effects.
AbstractPurposeTo investigate the safety and effectiveness of superselective prostatic artery embolization (PAE) in patients with benign prostatic hyperplasia (BPH).MethodsSixty-five patients diagnosed with BPH in Fujian Provincial Hospital between December 2014 and July 2019 were included. Patients with ineffective drug treatment after 6 months, who refused surgery, or who were unsuitable for surgery were included. We observed postoperative complications, followed up at 1, 3, and 6 months, compared clinical symptoms, and monitored changes in prostate-specific antigen (PSA) and prostatic volume (PV) before and a...
Prostate artery embolization (PAE) is a minimally invasive treatment option for benign prostatic hyperplasia (BPH) associated lower urinary tract symptoms (LUTS) (1-7). Operators require a detailed understanding of the prostate arterial anatomy (origins and collaterals) to ensure technical and clinical success with minimal complications (8). Because of the high variability in pelvic vascular anatomy, several classification systems have been developed to better identify and characterize prostate arteries.
In conclusion, this study provides novel evidence that febuxostat experimentally attenuates testosterone-induced BPH in rats, at least in part by inhibiting iNOS/COX-2 and VEGF/TGF-β pathways. PMID: 33031799 [PubMed - as supplied by publisher]
Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) occur in 50% of men over the age of 50 years, and prevalence increases with age. Patients traditionally have been managed with a combination of medical and surgical treatments. Transurethral resection of the prostate (TURP) is the gold standard for surgical treatment of BPH. Within the past decade, prostate artery embolization (PAE) has emerged as a minimally invasive alternative for the treatment of BPH, urinary retention, and hematuria of prostatic origin.
Medically refractory benign prostatic hyperplasia (BPH) induced lower urinary tract symptoms (LUTS) is an extremely prevalent issue in older men. The current gold standard therapy transurethral resection of the prostate (TURP) does produce urologic improvements but is also associated with higher than desired morbidity. This has led to the need to develop new minimally invasive means to treat this disease; prostate artery embolization (PAE) has emerged as one minimally invasive treatment option for these patients.
Hematuria of prostatic origin has multiple etiologies including benign prostatic hyperplasia (BPH), iatrogenic urological trauma, prostate cancer, and radiation therapy. Hematuria secondary to benign prostatic hyperplasia (BPH) can occur because of the increased vascularity of the primary gland, itself, or because of the vascular re-growth following a transurethral resection of the prostate. Prostatic hematuria usually resolves with conservative measures; however, refractory hematuria of prostatic origin (RHPO) may require hospitalization with treatment with blood transfusions, repeated indwelling urinary catheterization, ...
Many interventions to treat men with benign prostatic hyperplasia (BPH) associated lower urinary tract symptoms (LUTS) are associated with sexual side effects or complications, such as hematospermia, erectile dysfunction, or ejaculatory dysfunction. As loss of sexual function can significantly impact quality of life, an optimal treatment for BPH associated LUTS would be one without any sexual dysfunction side effects. Prostatic artery embolization (PAE) is a minimally invasive treatment for men with BPH associated LUTS.